Skye Bioscience, Inc.
- SKYE
- NASDAQ
- Biotechnology
- Obesity/Metabolic Disease Therapies
- GPCR Targeted Drugs
- Clinical-Stage Biotech
$1.53
Today −1.29%Quote Oct 19, 2026, 08:00 PM UTC
−1.27%over the last month
Max drawdown −15.0%From 1-month high −13.9%3 months −70.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Skye Bioscience
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
2
Market value
$54.2M
Quote Oct 19
Floor
$1.50
2.0% below price
Resistance
$1.54
0.9% above price
Price vs analyst targets
5 analysts
Lowest target
$2.00Highest target
$21.00
$2.00Highest target
$21.00
- Price $1.53
- Average target $12.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 684% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SKYEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free